友霖 攜手 Actavis (Watson) 首仿Pitavastatin 試水溫 (學名藥3大巨頭TEVA, Sandos, Actavis)

友霖攜手Actavis搶攻美降血脂藥市場 今富族網記者吳泓駿／報導 2014-09-05友霖生技（4166）於昨（4）日宣佈和全球第三大藥品製藥商 Actavis 正式簽約，雙方攜手合作以拓展降血脂學名藥Pitavastatin的美國市場。友霖已向美國FDA申請該藥品專利，一旦未來取得FDA核發的藥證，不只能擁有在美國市場的180天獨家專賣權，同時可藉由Actavis的通路佈建，搶攻每年約1.55億美元的商機。友霖生技成立於2008年，為友華生技（4120）旗下轉投資事業，專注於藥物研發及製造。友霖表示，本次開發的藥品Pitavastatin是一種降血脂用藥，療效佳且副作用低，同時和糖尿病藥物併用，較不會增高糖化血色素，目前該藥品在美國挑戰原廠專利大有進展，在國內也已經取得上市許可，現正於各大醫療院所進藥中。Actavis plc為美國上市製藥公司，專注於研發、製造與銷售各種學名藥以及創新產品給全球病患。友霖本次與Actavis plc簽訂合約，友霖將依據合約在不同里程碑向Actavis取得授權金，未來雙方將共同面對挑戰專利的經費與司法程序。藥品核准上市後，友霖生技擁有藥證與專利技術獨家持有權，並負責藥物生產製造，Actavis將負責全美的通路與銷售，銷售利潤則由雙方共享。友霖生技目前股本16.81億元，根據合併財報，2012年營收1.49億元，稅前虧損2.48億元，每股稅後虧損1.17元；2013年營收1.8億元，稅前虧損2.12億元，每股稅後虧損1.05元；累計2014年上半年營收8,950萬元，稅前虧損9,693萬元，每股稅後虧損0.47元。

Watson becomes Actavis, and already future is muted  January 25, 2013 | By Eric Palmer  Watson Pharmaceuticals is no more. The generic drug company has officially taken the name of its most recent acquisition target, Actavis ($ACT), thinking it has better brand recognition in the markets where it intends to expand. In guidance today, however, the company said that growth will not be quite as fast this year as analysts had expected, Reuters reports. The $5.5 billion Actavis merger, completed in November, propelled the company into third place among the world's generics makers, behind Teva Pharmaceuticals ($TEVA) and Novartis' ($NVS) Sandoz unit. But CEO Paul Bisaro said the deal also would allow Watson, now Actavis, not only to play on a global stage but also to build up a branded drug business to supplement lower-margin generics. Growth is the very reason that the company chose take the Actavis moniker. The former Iceland-based company has a strong brand ID in some emerging markets where the combined company intends to grow the most. Bisaro said the combined company would be able to carve about $300 million in annual operating costs out of the combined company in the next three years. Still, this year will be a challenge for growth. According to Reuters, Actavis today projected earnings per share this year in the range of $7.70 to $8.10 per share, while analysts on average were looking for $8.20 per share.